Pharmacokinetic non-interaction analysis in a fixed-dose formulation in combination of atorvastatin and ezetimibe

Frontiers in Pharmacology

Volumn 5, Issue NOV, 2014, Pages

  Omar, Patiño Rodríguez ^a   Irma, Torres Roque ^a   Maricela, Martínez Delgado ^a   Abraham, Escobedo Moratilla ^a,c   José, Pérez Urizar ^b  

^a Dixpertia Investigacion Biofarmaceutica y Farmacologica SC San Luis Potosi   (Mexico)

^b UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

^c INSTITUTO POTOSINO DE INVESTIGACIÓN CIENTÍFICA Y TECNOLÓGICA   (Mexico)

Author keywords

Atorvastatin; Ezetimibe; Lc ms ms; Pharmacokinetic drug drug interaction; Statins

Indexed keywords

ATORVASTATIN PLUS EZETIMIBE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG CAPSULE; DRUG FORMULATION; FEMALE; HUMAN; HUMAN EXPERIMENT; LONGITUDINAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MEXICAN; NORMAL HUMAN; OPEN STUDY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

EID: 84926450611     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2014.00261     Document Type: Article

References (37)

1. Bahrami, G., Mohammadi, B., Mirzaeei, S., Kiani, A. (2005). Determination of atorvastatin in human serum by reversed-phase high-performance liquid chromatography with UV detection. J Chromatogr B. 826:41-5
2. Bahrami, G., Mohammadi, B., Khatabi, P.M., Farzaei, M.H., Majnooni, M.B., Bahoosh, S.R. (2010). Application of one-step liquid chromatography-electrospray tandem MS/MS and collisioninduced dissociation to quantification of ezetimibe and identification of its glucuronated metabolite in human serum: A pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 15:2789-95
3. Ballantyne, C.M., Abate, N., Yuan, Z., King, T.R., Palmisano, J. (2005). Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J. 149: 464-73
4. Bennett, S., Sager, P., Lipka, L., Melani, L., Suresh, R., Veltri, E. (2004). Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men. J Womens Health 13:1101-1107
5. Bhatt, K.K., Shankar, M.B., Patel, J.B., Christian, M.C. (2010). Simultaneous Estimation of Atorvastatin Calcium And Ezetimibe In Tablet By RP-HPLC Method. Int J Pharm App Sci. 1:114-117
6. Drugbank. Atorvastatin. May 12, 2014. Available in: http://www.drugbank.ca/drugs/DB01076
7. European Medicines Agency (EMEA). 2010. EMEA/CHMP, Doc. Ref. CPMP/EWP/QWP/1401/98. July01,2014.http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/201 0/01/WC500070039.pdf
8. Ezzet, E., Krishna, G., Wexler, D.B., Statkevich, P., Kosoglou, T., Batra, V.K. (2001). Clin. Ther. 23: 871
9. Hauschke, D., Steinijans, V., Pigeot, I. (2007). Analysis of pharmacokinetic interactions. In: Bioequivalence studies in drug development. Methods and application. Wiley & Sons LTD. West Sussex. 175-177p
10. Hauschke, D., Steinijans, V., Pigeot, I. (2007). Analysis of pharmacokinetic interactions. In: Bioequivalence studies in drug development. Methods and Applications. 175-177
11. Heinonen, T.M., Stein, E., Weiss, S.R., McKenney, J.M., Davidson, M., Shurzinske, L., Black, D.M. (1996). The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: Results of a randomized, double-masked study. Clin Ther.18:853-863
12. Jacobson, T.A. (2004). Comparative Pharmacokinetic Interaction Profiles of Pravastatin, Simvastatin, and Atorvastatin When Coadministered With Cytochrome P450 Inhibitors. Am J Cardiol. 94:1140-1146
13. Jones, P., Kafonek, S., Laurora, I., Hunninghake, D. (1998). Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia. Am J Cardiol. 81:582-587
14. Kakara, M., Nomura, H., Fukae, M., Gotanda, K., Hirota, T., Matsubayashi, S., Shimomura, H., Hirakawa, M., Ieiri, I. (2014). Population pharmacodynamic analysis of LDL-cholesterol lowering effects by statins and co-medications based on electronic medical records. Br J Clin Pharmacol. doi: 10.1111/bcp.12405
15. Koytchev, R., Ozalp, Y., Erenmemisoglu, A., van der Meer, M.J., Alpan, R.S. (2004). Bioequivalence study of atorvastatin tablets. Arzneimittelforschung. 54:573-7
16. Kosoglou, T., Statkevich, P., Johnson-Levonas, A.O., Paolini, J.F., Bergman, A.J., Alton, K.B. (2005). Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 44: 467-94
17. Kosoglou, T., Meyer, I., Veltri, E.P., Statkevich, P., Yang, B., Zhu, Y., Mellars, L., Maxwell, S.E., Patrick, J.E., Cutler, D.L., Batra, V.K., Affrime, M.B. (2002). Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and atorvastatin. Br J Clin Pharmacol. 54:309-19
18. Lennernäs, H. (2003). Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet.42:1141-1160
19. Li, S., Liu, G., Jia, J., Li, X., Yu, C. (2006). Liquid chromatography-negative ion electrospray tandem mass spectrometry method for the quantification of ezetimibe in human plasma. J Pharm Biomed Anal. 3: 987-92
20. Liu, Y.M., Pu, H.H., Liu, G.Y., Jia, J.Y., Weng, L.P., Xu, R.J., Li, G.X., Wang, W., Zhang, M.Q., Lu, C., Yu, C. (2010). Pharmacokinetics and Bioequivalence Evaluation of Two Different Atorvastatin Calcium 10-mg Tablets: A Single-Dose, Randomized-Sequence, Open-Label, Two-Period Crossover Study in Healthy Fasted Chinese Adult Males. Clin Ther. 7:1396-407
21. Mahley, R.W., Bersot, T.P. (2008). The Pharmacological Basis of Therapeutics. The McGraw-Hill Companies, New York, NY. 605
22. Malloy, M.J., Kane, J.P. (2007). Basic and Clinical Pharmacology. The McGraw-Hill Companies, New York, NY. 675
23. Nawrocki, J.W., Weiss, S.R., Davidson, M.H., Sprecher, D.L., Schwartz, S.L., Lupien, P.J., Jones, P.H., Haber, H.E., Black, D.M. (1995). Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 15: 678-682
24. NOM-177-SSA1-1998: Tests and procedures to demonstrate interchangeability between pharmaceutical formulations (in Spanish). Mexican Health Ministry. Mexico (1998). http://www.ssa.gob.mx/unidades/cdi/nom/177ssa18.html or http://www.feum.org/legisla/NOM-177PruebInter7may99.pdf. Accessed January 15, 2013
25. Okada, K., Iwahashi, N., Endo, T., Himeno, H., Fukui, K., Kobayashi, S., Shimizu, M., Iwasawa, Y., Morita, Y., Wada, A., Shigemasa, T., Mochida, Y., Shimizu, T., Sawada, R., Uchino, K., Umemura, S., Kimura, K. (2012). Long-term effects of ezetimibe-plus-statin therapy on lowdensity lipoprotein cholesterol levels as compared with double-dose statin therapy in patients with coronary artery disease. Atherosclerosis. 224:454-456
26. Patrick, J.E., Kosoglou, T., Stauber, K.L., Alton, K.B., Maxwell, S.E., Zhu, Y., Statkevich, P., Iannucci, R., Chowdhury, S., Affrime, M., Cayen, M.N. (2002). Drug Metab Dispos. 30: 430
27. Pfizer Inc. Lipitor® (2009) (atorvastatin calcium) full prescribing information
28. Posvar, E.L., Radulovic, L.L., Cilla, D.D., Whitfield, L.R., Sedman, A.J. (1996). Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects. J Clin Pharmacol. 8:728-31
29. Rowland, M., Tozer, T. (2011). Clinical Pharmacokinetics. Concepts and Applications. Editorial Lippincott Williams & Wilkins
30. Sistla, R., Tata, V.S., Kashyap, Y.V., Chandrasekar, D., Diwan, P.V. (2005). Development and validation of a reversed-phase HPLC method for the determination of ezetimibe in pharmaceutical dosage forms. J Pharm Biomed Anal. 15: 517-22
31. Van Heek, M., Farley, C., Compton, D.S., Hoos, L., Alton, K.B., Sybertz, E.J., Davis, H.R. (2000). Br. J. Pharmacol. 129:1748
32. Van Heek, M., Davis, H. (2002). Pharmacology of ezetimibe. Eur Heart J. 4 (Supplement J): J5-J8
33. Van Rooyen, D.M., Gan, L.T., Yeh, M.M., Haigh, W.G., Larter, C.Z., Ioannou, G., Teoh, N.C., Farrell, G.C. (2013). Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome. J Hepatol. 59:144-52
34. Williams, E.J. (1949). Experimental Designs Balanced for the Estimation of Residual Effects of Treatments. Aus J Scie Res. 2: 149-168
35. Zetia. July 05, 2014. http://www.druglib.com/druginfo/zetia/description_pharmacology
36. Zhang, L., Zhang, Y.D., Zhao, P., Huang, S.M. (2009). Predicting drug-drug interactions: an FDA perspective. AAPS J. 11:300-6
37. Zhu, Y., Statkevich, P., Kosoglou, T. (2001). Lack of a pharmacokinetic interaction between ezetimibe and atorvastatin. Clin Pharmacol Ther. 69: 68